SOUTH SAN FRANCISCO, Calif., July 1 /PRNewswire-FirstCall/ -- Monogram
Biosciences, Inc. (Nasdaq: MGRM) announced today that William D. Young, CEO
and Chairman, is scheduled to present an update on the company's business
at the Collins Stewart LLC Fourth Annual Growth Conference on Tuesday, July
8, 2008 at 9:00 a.m. (Eastern Time) at the Mandarin Oriental Hotel in New
York, NY.
To access the live audio broadcast or the subsequent archived
recording, log on to http://www.monogrambio.com and go to the investor
relations section ("Investors/Media" tab) and click on the "Events &
Webcasts" link provided on the sidebar menu on the page.
About Monogram Biosciences, Inc.
Monogram is advancing individualized medicine by discovering,
developing and marketing innovative products to guide and improve treatment
of serious infectious diseases and cancer. The Company's products are
designed to help doctors optimize treatment regimens for their patients
that lead to better outcomes and reduced costs. The Company's technology is
also being used by numerous biopharmaceutical companies to develop new and
improved antiviral therapeutics and vaccines as well as targeted cancer
therapeutics. More information about the Company and its technology can be
found on its web site at http://www.monogrambio.com
contacts: Alfred G. Merriweather Jeremiah Hall
Chief Financial Officer Feinstein Kean Healthcare
Tel: 650 624-4576 Tel: 415 677-2700
amerriweather@monogrambio.com jeremiah.hall@fkhealth.com
SOURCE Monogram Biosciences, Inc.
 back to top
Related links:
http://www.monogrambio.com
CONTACT:
Alfred G. Merriweather, Chief Financial
Officer of Monogram Biosciences, Inc., +1-650-624-4576,
amerriweather@monogrambio.com; Jeremiah Hall of Feinstein Kean
Healthcare, +1-415-677-2700, jeremiah.hall@fkhealth.com
|
